FHA
NTLA icon

First Horizon Advisors’s Intellia Therapeutics NTLA Stock Holding History

First Horizon Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$14.9K Sell
1,591
-849
-35% -$6.97K ﹤0.01% 1524
2025
Q1 		$17.3K Sell
2,440
-493
-17% -$4.98K ﹤0.01% 1385
2024
Q4 		$34.2K Buy
2,933
+259
+10% +$4.04K ﹤0.01% 1124
2024
Q3 		$55K Buy
2,674
+70
+3% +$1.61K ﹤0.01% 941
2024
Q2 		$58.3K Buy
2,604
+472
+22% +$11.2K ﹤0.01% 856
2024
Q1 		$58.7K Buy
2,132
+176
+9% +$4.89K ﹤0.01% 880
2023
Q4 		$59.6K Sell
1,956
-388
-17% -$11.2K ﹤0.01% 842
2023
Q3 		$74.1K Sell
2,344
-806
-26% -$31.3K ﹤0.01% 709
2023
Q2 		$128K Sell
3,150
-200
-6% -$8.11K ﹤0.01% 578
2023
Q1 		$125K Sell
3,350
-5
-0.1% -$196 ﹤0.01% 587
2022
Q4 		$117K Buy
3,355
+80
+2% +$3.8K ﹤0.01% 576
2022
Q3 		$183K Sell
3,275
-236
-7% -$14.6K 0.01% 456
2022
Q2 		$181K Buy
+3,511
New +$178K 0.01% 484
2022
Q1 		– Sell
-1,327
Closed -$155K – 2101
2021
Q4 		$155K Buy
1,327
+106
+9% +$13.3K ﹤0.01% 557
2021
Q3 		$163K Buy
1,221
+224
+22% +$33.9K 0.01% 546
2021
Q2 		$160K Sell
997
-22
-2% -$1.71K 0.01% 437
2021
Q1 		$81K Buy
+1,019
New +$68.4K ﹤0.01% 569

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Horizon Advisors's NTLA Position: Q2 2025 in Review

First Horizon Advisors reduced its Intellia Therapeutics (NTLA) stake by 35% in Q2 2025, selling an estimated $6.97K and leaving 1,591 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

First Horizon Advisors first reported a position in NTLA in Q1 2021 and has held it in 17 quarters since. The position peaked at $183K in Q3 2022. 281 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • First Horizon Advisors held 1,591 shares of Intellia Therapeutics worth $14.9K as of Q2 2025.
  • First Horizon Advisors sold 849 Intellia Therapeutics shares in Q2 2025, an estimated $6.97K.
  • Intellia Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1524 holding.
  • First Horizon Advisors first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • First Horizon Advisors's Intellia Therapeutics position peaked at $183K in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.